Background: Aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD) requires lifelong immunosuppression to prevent relapses and disability. However, long-term treatment can increase the risk of severe and opportunistic infections, which can lead to hospitalisation and death. Objectives: To describe severe infections in AQP4-IgG NMOSD, their outcomes and risk factors, to inform safer long-term management. Methods: We retrospectively analysed prospectively collected data from 209 patients with AQP4-IgG NMOSD treated with immunosuppressive therapies and followed ⩾1 year at a UK national specialist service. Severe infections were defined as requiring intravenous therapy or hospitalisation. Predictors were identified using multivariate regression. Results: Forty-nine severe/opportunistic infections occurred in 37 patients (18%), accounting for one-third of deaths (10/30). Independent predictors were longer disease duration (OR 1.10, 95% CI 1.01–1.21), older age at onset (OR 1.04, 95% CI 1.00–1.08), comorbid autoimmune disease (OR 3.91, 95% CI 1.95–7.84) and diabetes mellitus (OR 7.48, 95% CI 2.24–24.98). Four patients died after their first infection. Among survivors, nine developed recurrent infections, six of whom died. Conclusions: Severe infections can be a complication of immunosuppression in NMOSD, especially in older patients and those with comorbidities. Risk stratification, comorbidity management and infection prevention should guide therapy to balance safety and relapse control

Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

Greco Giacomo
Investigation
;
2026-01-01

Abstract

Background: Aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD) requires lifelong immunosuppression to prevent relapses and disability. However, long-term treatment can increase the risk of severe and opportunistic infections, which can lead to hospitalisation and death. Objectives: To describe severe infections in AQP4-IgG NMOSD, their outcomes and risk factors, to inform safer long-term management. Methods: We retrospectively analysed prospectively collected data from 209 patients with AQP4-IgG NMOSD treated with immunosuppressive therapies and followed ⩾1 year at a UK national specialist service. Severe infections were defined as requiring intravenous therapy or hospitalisation. Predictors were identified using multivariate regression. Results: Forty-nine severe/opportunistic infections occurred in 37 patients (18%), accounting for one-third of deaths (10/30). Independent predictors were longer disease duration (OR 1.10, 95% CI 1.01–1.21), older age at onset (OR 1.04, 95% CI 1.00–1.08), comorbid autoimmune disease (OR 3.91, 95% CI 1.95–7.84) and diabetes mellitus (OR 7.48, 95% CI 2.24–24.98). Four patients died after their first infection. Among survivors, nine developed recurrent infections, six of whom died. Conclusions: Severe infections can be a complication of immunosuppression in NMOSD, especially in older patients and those with comorbidities. Risk stratification, comorbidity management and infection prevention should guide therapy to balance safety and relapse control
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1550575
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact